Fertility News and Research

RSS

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Female biology screens for the best sperm: Study

A new study has revealed that the female reproductive system is ‘choosy’ when it comes to inferior quality sperm and rejects the ‘advances’ of spermatozoa that are not good enough to create a pregnancy.

23 Jun 2010

Exposure to BPA in early life may affect testis function into adulthood

Exposure to environmental levels of the industrial chemical bisphenol A, or BPA, in the womb and early life may cause long-lasting harm to testicular function, according to a new study conducted in animals. The results are being presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Vitrolife acquires 25% participation in HertART Aps

Vitrolife has entered an agreement with the Danish company HertART Aps with regard to product development and distribution of IVF products and at the same time acquires a participation of 25 percent in the company.

18 Jun 2010

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome vaccine) clinical program in patients with non-small cell lung cancer (NSCLC) which includes the Phase III studies, STARTa and INSPIREb. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees.

17 Jun 2010

Fertility drugs cause multiple and premature births

The widespread use of fertility drugs, not just high-tech laboratory procedures, plays a major role in causing multiple births and contributes to the problem of premature birth in the United States, experts said today at the March of Dimes National Communications Advisory Council luncheon.

17 Jun 2010

Hamilton Thorne announces launch of Staccato multi-pulse laser system at 8th ISSCR Annual Meeting

Hamilton Thorne Ltd., a leading provider of advanced laser systems and instruments for the stem cell research and fertility clinic markets, today announced the launch of the Staccato(TM) multi-pulse laser system at the 8th Annual Meeting of the International Society of Stem Cell Research (ISSCR), June 16-19, 2010, in San Francisco, CA. Staccato(TM) will add to the functionality of the XYClone(R) laser system, providing the ability of near-continuous application of the laser to the sample through rapid pulsing of the beam.

16 Jun 2010

Vitro, HemoGenix launch new stem cell testing products at International Society for Stem Cell Research meeting

Vitro Diagnostics, Inc., dba Vitro Biopharma, and HemoGenix®, Inc. announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting being held in San Francisco, CA this week. This meeting is being attended by over 3,000 participants from leading academic institutions and commercial stem cell firms throughout the world.

16 Jun 2010

Tel Aviv University research suggests link between IVF treatments and autism

The first "test tube baby" was born in 1978. With advances in reproductive science, an estimated one percent of all American babies are now born each year through in vitro fertilization. But IVF and other assisted fertility treatments may be solving one problem by creating another, suggests new evidence from Tel Aviv University.

15 Jun 2010

Female endurance sports athletes are at risk for serious health issues, say physicians

Female endurance sports athletes may be at risk for serious health issues, according to physicians at Loyola University Health System. Excessive exercise and inadequate nutrition can lead to problems such as low energy, menstrual irregularity, fertility issues, stress fractures and osteoporosis.

15 Jun 2010

FDA clears U.Va.'s SpermCheck Fertility at-home test

Couples will soon have a new tool in diagnosing male infertility - without the expense and inconvenience associated with a trip to a specialist's office.

14 Jun 2010

Vitrolife enters into two year collaboration agreement with University of Melbourne

Vitrolife has entered into a two year collaboration agreement with University of Melbourne regarding collaboration with the stem cells expertise of the development of clinical grade stem cell media.

14 Jun 2010

In vitro fertilization ups the risk of birth defects: study

Researchers have found from a large scale study that in vitro fertilization of IVF is associated with an increased risk of birth defects in the baby. They urge doctors treating patients with infertility to routinely warn them about these risks. The study involved 33 centers for IVF in France and covered over 15,000 births from 2003 to 2007. This study is the largest till date.

14 Jun 2010

Emerging health care models and approaches discussed at 2010 Health Care Conference

Dr. Sanford J. Siegel, president and CEO of Chesapeake Urology Associates, Maryland, was a featured panelist at the 2010 Health Care Conference for health care community executives, held at the BWI Marriott in Baltimore on June 7, 2010.

10 Jun 2010

Personality traits influence reproductive success

The reproductive success of both men and women is influenced by our personality traits, according to new research from the University of Sheffield.

9 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

7 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Fertility News and Research

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Female biology screens for the best sperm: Study

Exposure to BPA in early life may affect testis function into adulthood

Vitrolife acquires 25% participation in HertART Aps

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

Fertility drugs cause multiple and premature births

Hamilton Thorne announces launch of Staccato multi-pulse laser system at 8th ISSCR Annual Meeting

Vitro, HemoGenix launch new stem cell testing products at International Society for Stem Cell Research meeting

Tel Aviv University research suggests link between IVF treatments and autism

Female endurance sports athletes are at risk for serious health issues, say physicians

FDA clears U.Va.'s SpermCheck Fertility at-home test

Vitrolife enters into two year collaboration agreement with University of Melbourne

In vitro fertilization ups the risk of birth defects: study

Emerging health care models and approaches discussed at 2010 Health Care Conference

Personality traits influence reproductive success

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News